Dollar Tree (Family Dollar) vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Major US discount retailer operating 16,000+ Dollar Tree stores; sold Family Dollar in 2025 for $1B vs $8.5B purchase price; pivoting to multi-price strategy up to $7; Norfolk Virginia-based retailer refocusing on its core single-price-point brand strength.
About
Dollar Tree is a major US discount retailer founded in 1986 in Norfolk, Virginia, operating the Dollar Tree and (formerly) Family Dollar banners. The company built its brand on the single-price-point model — everything for $1 — which created a simple, powerful value proposition for budget-conscious shoppers. Dollar Tree acquired Family Dollar in 2015 for $8.5 billion in a transformative deal intended to expand its footprint in urban and rural low-income markets.\n\nDollar Tree operates more than 16,000 stores across the United States and Canada under the Dollar Tree banner. After years of struggling to integrate Family Dollar, the company sold the Family Dollar banner in 2025 for $1 billion — a significant write-down from its acquisition price — and pivoted its full strategic attention to the Dollar Tree brand. The company has shifted away from the rigid $1 price point to a multi-price strategy with items priced up to $7, allowing it to carry higher-quality and larger-format products that improve margins.\n\nDollar Tree generates approximately $30 billion in annual revenue and is one of the largest brick-and-mortar retailers in the United States. The sale of Family Dollar marks a strategic reset as the company focuses on store renovation, assortment upgrades, and the multi-price format to compete more effectively against Walmart, Dollar General, and deep-discount e-commerce. In 2025–2026, Dollar Tree has been remodeling stores to the new format and testing expanded consumables and seasonal categories to drive trip frequency.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.